January 7, 2022. The Court in the Acer Therapeutics securities matter (Southern District of New York) approved a class action settlement in the amount of $8.35 million. Plaintiffs alleged that Acer misled investors about the true likelihood of and timeline for FDA approval of the company’s drug to treat vascular Ehlers-Danlos Syndrome. Plaintiffs retained Crowninshield Financial Research to consult on the computation of damages.


Additional information is available at The Rosen Law Firm.